Premium Industrial News

China's Pharmaceutical Companies Turn Attention to Monoclonal Antibodies

China's Pharmaceutical Companies Turn Attention to Monoclonal Antibodies

pharmaceutical

Industry Segment: Pharmaceutical & Biotech | Word Count: 150 Words
Attachment: China mAbs 0621

BEIJING, CHINA--Researched by Industrial Info Resources (Sugar Land, Texas)--According to the quarterly financial reports from China's listed pharmaceutical companies, Jiangsu Hengrui Medicine Company Limited has 40 new drugs under development, the most of any Chinese firm, followed by Jiangsu Chia Tai-Tianqing Pharmaceutical Company Limited with 34, and Shanghai Junshi Biosciences Company Limited with 20.

This Premium Article can be purchased individually or as part of a subscription

Subscribe Now!(All Fields Required)

Subscription Type:

  • Pay-Per-Article - $5.95
  • Annual Premium News Subscription - $365.00
Pricing Help?